Public Employees Retirement Association of Colorado boosted its holdings in Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) by 79.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 18,346 shares of the specialty pharmaceutical company’s stock after purchasing an additional 8,123 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Jazz Pharmaceuticals were worth $2,470,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP increased its position in shares of Jazz Pharmaceuticals by 49.1% during the second quarter. Dimensional Fund Advisors LP now owns 229,898 shares of the specialty pharmaceutical company’s stock valued at $35,750,000 after purchasing an additional 75,703 shares during the period. AXA increased its position in shares of Jazz Pharmaceuticals by 23.2% during the third quarter. AXA now owns 116,862 shares of the specialty pharmaceutical company’s stock valued at $17,091,000 after purchasing an additional 22,007 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Jazz Pharmaceuticals during the third quarter valued at approximately $296,000. Schroder Investment Management Group bought a new stake in shares of Jazz Pharmaceuticals during the third quarter valued at approximately $52,571,000. Finally, Orbimed Advisors LLC increased its position in shares of Jazz Pharmaceuticals by 16.0% during the third quarter. Orbimed Advisors LLC now owns 749,200 shares of the specialty pharmaceutical company’s stock valued at $109,571,000 after purchasing an additional 103,300 shares during the period. 93.05% of the stock is currently owned by institutional investors.

Shares of Jazz Pharmaceuticals plc – (JAZZ) opened at $141.41 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.10 and a quick ratio of 2.94. The company has a market capitalization of $8,388.27, a price-to-earnings ratio of 23.30, a P/E/G ratio of 0.74 and a beta of 0.99. Jazz Pharmaceuticals plc – has a one year low of $128.58 and a one year high of $163.75.

A number of research firms have recently issued reports on JAZZ. Deutsche Bank set a $170.00 price objective on Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, January 16th. B. Riley restated a “buy” rating and set a $206.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, January 16th. Zacks Investment Research upgraded Jazz Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 12th. Piper Jaffray Companies set a $177.00 price objective on Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, October 21st. Finally, Cantor Fitzgerald restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Sunday, December 10th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and seventeen have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $178.51.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 3,000 shares of the business’s stock in a transaction on Friday, January 12th. The stock was sold at an average price of $150.00, for a total value of $450,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Patrick G. Enright sold 352 shares of the business’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $133.19, for a total value of $46,882.88. Following the completion of the transaction, the director now directly owns 1,365 shares in the company, valued at approximately $181,804.35. The disclosure for this sale can be found here. In the last ninety days, insiders sold 21,452 shares of company stock worth $2,985,885. 4.30% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: This piece was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://theolympiareport.com/2018/02/14/jazz-pharmaceuticals-plc-jazz-holdings-lifted-by-public-employees-retirement-association-of-colorado.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc – (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.